Recombinant Human Coagulation Factor IX Protein, CF
Recombinant Human Coagulation Factor IX Protein, CF Summary
Product Specifications
Thr29-Thr461, with a C-terminal Fc tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
9260-SE
| Formulation | Supplied as a 0.2 μm filtered solution in Tris and NaCl. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Assay Procedure
- Assay Buffer: 100 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij-35, pH 8.0
- Recombinant Human Coagulation Factor IX (rhFactor IX) (Catalog # 9260-SE)
- Bacterial Thermolysin (Thermolysin) (Catalog # 3097-ZN)
- Substrate: Fluorogenic Peptide Substrate II, MCA-Arg-Pro-Lys-Pro-Val-Glu-NVAL-Trp-Arg-Lys(DNP)NH2 (Catalog # ES002)
- 1,10-Phenanthroline (Sigma, Catalog # 320056)
- F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
- Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
- Activate rhFactor IX at 100 µg/mL wih 10 µg/mL Thermolysin in Assay Buffer.
- Incubate at 37 °C for 90 minutes.
- Stop the reaction by adding 1,10-Phenanthroline to the reaction tube at a final concentration of 10 mM.
- Dilute activated rhFactor IX to 4 ng/µL in Assay Buffer.
- Dilute Substrate to 20 µM in Assay Buffer.
- Load 50 µL of the 4 ng/µL rhFactor IX into a black well plate, and start the reaction by adding 50 µL of 20 µM Substrate. Include a Substrate Blank containing 50 µL Assay Buffer and 50 µL 20 µM Substrate.
- Read at excitation and emission wavelengths of 320 nm and 405 nm (top read), respectively, in kinetic mode for 5 minutes.
- Calculate specific activity:
Specific Activity (pmol/min/µg) = | Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU) |
| amount of enzyme (µg) |
*Adjusted for Substrate Blank
**Derived using calibration standard MCA-Pro-Leu-OH (Bachem, Catalog # M-1975)
- rhFactor IX: 0.2 µg
- Substrate: 10 µM
Scientific Data
View Larger
Reconstitution Calculator
Background: Coagulation Factor IX
Coagulation Factor IX, also known as Christmas Factor, is a secreted by the liver and plays a key role in the activation of the intrinsic clotting cascade (1). Factor IX consists of a Gla domain, two tandem EGF-like domains, an activation peptide, and an S1 serine protease domain (2). Mature human Factor IX shares approximately 81% amino acid sequence identity with mouse and rat Factor IX. Alternative splicing generates an additional isoform that lacks the first EGF-like domain. The Gla domain is modified by Vitamin K-dependent gamma-carboxylation and mediates the association of Factor IX with phospholipid bilayers (3, 4). The activation peptide is removed by Factor XIa mediated cleavage, resulting in heavy and light chains that remain disulfide-linked (5). Factor IX can also be activated by proteolytic factors in multiple snake venoms (6, 7). Active Factor IX associates with Factor VIIIa on the platelet surface where it cleaves and activates Factor X, leading to Fibrin deposition and clot formation (8-10). The human Factor IX gene is highly polymorphic, and Hemophilia B can be caused by X-linked deficiency of Factor IX activity (11-14).
- Smith, S.A. et al. (2015) Crit. Rev. Biochem. Mol. Biol. 50:326.
- Kurachi, K. and E.W. Davie (1982) Proc. Natl. Acad. Sci. USA 79:6461.
- Rawala-Sheikh, R. et al. (1992) Blood 79:398.
- Freedman, S.J. et al. (1996) J. Biol. Chem. 271:16227.
- Di Scipio, R.G. et al. (1978) J. Clin. Invest. 61:1528.
- Takeya, H. et al. (1992) J. Biol. Chem. 267:14109.
- Sajevic, T. et al. (2011) Toxicon 57:627.
- Ahmad, S.S. et al. (2003) J. Thromb. Haemost. 1:2348.
- Mathur, A. et al. (1997) J. Biol. Chem. 272:23418.
- van Dieijen, G. et al. (1985) Thromb. Haemost. 53:396.
- Aguilar-Martinez, P. et al. (1994) Hum. Genet. 94:287.
- Davis, L.M. et al. (1987) Blood 69:140.
- Bertina, R.M. et al. (1990) J. Biol. Chem. 265:10876.
- Girolami, A. et al. (2015) Semin. Thromb. Hemost. 41:359.
Citation for Recombinant Human Coagulation Factor IX Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence
Authors: P Carpintero, M Borghesan, O Eleftheria, B Pan-Castil, JA Fafián-Lab, TP Mitchell, A Yuste, M Ogrunc, TD Nightingal, M Mayan, A O'Loghlen
Cell Death & Disease, 2022-02-19;13(2):163.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human Coagulation Factor IX Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Coagulation Factor IX Protein, CF and earn rewards!
Have you used Recombinant Human Coagulation Factor IX Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
